Novo Nordisk Gains Strategic Edge with Oral Wegovy Approval

A pivotal regulatory decision by the U.S. Food and Drug Administration (FDA) has refocused investor attention on Novo Nordisk. The agency's late December clearance of an oral formulation for the weight-loss drug Wegovy (semaglutide) provides the company with a potential new growth engine from 2026 onward. The central challenge now shifts to execution, as Novo Nordisk must navigate an increasingly competitive landscape to successfully launch this product.

In a move designed to capture market share rapidly, Novo Nordisk has set an aggressive launch price of approximately $149 per month for the oral therapy. This pricing strategy serves a dual purpose: undercutting potential rivals and aligning with emerging political frameworks in the United States. The company is targeting a swift commercial rollout, with plans for the tablet to become available in the U.S. by early January 2026.

Market analysts note that the oral version offers comparable efficacy in weight reduction to its injectable counterpart, while significantly improving patient convenience by eliminating the need for injections. This convenience factor is expected to lower the barrier to treatment for many patients.

Navigating the U.S. Political and Regulatory Landscape

The product launch coincides with critical developments in U.S. healthcare policy. Reports indicate that Novo Nordisk has reached an understanding with the incoming U.S. administration. The reported agreement centers on offering significantly reduced prices for weight-management medications in federal programs—around $149 monthly—in exchange for favorable trade terms and expedited regulatory reviews.

This proactive engagement is strategically timed ahead of newly negotiated Medicare pricing set to take effect in January 2026. The company's aim is to mitigate risks associated with potential tariffs that could impact profitability in its most crucial market.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Financial Performance and Competitive Context

Behind the optimism generated by the FDA approval lies a more mixed financial picture from the previous year. For the third quarter of 2025, earnings per American Depositary Receipt (ADR) came in at $0.70, missing the consensus estimate of $0.77. This earnings shortfall, against high market expectations, contributed to weaker share performance in the latter half of the year.

While revenue continued to grow, it lagged behind the growth rates of key competitors. The comparison with Eli Lilly's Zepbound has intensified debates over valuation and market share. In this context, the oral Wegovy approval gains added significance, offering a tangible pathway to reinvigorating sales growth from 2026.

Competition is also heating up in international markets. In India, Novo Nordisk is in a tight race with Eli Lilly to establish dominance in the obesity segment before lower-cost generics potentially enter the market after March 2026. The company introduced Ozempic there in late 2025, employing assertive pricing and distribution tactics to secure an early foothold.

Key Data Points

• Share Price: Shares closed at $52.56 on December 24, demonstrating recent positive momentum.
• Product Milestone: Oral Wegovy (semaglutid) received FDA approval; U.S. launch is scheduled for January 2026.
• Pricing: Launch price is set at approximately $149 per month, aimed at rapid market penetration and aligning with political considerations.
• Recent Earnings: Q3 2025 profit was $0.70 per ADR, below the $0.77 consensus estimate.
• Year-to-Date Performance: The stock has partially recovered following a decline of nearly 40% earlier in the year.

Outlook and Implementation Risks

The market is now closely watching Novo Nordisk's next steps. While the medium-term growth narrative remains intact in the view of many observers, near-term equity performance is heavily dependent on the U.S. launch execution for oral Wegovy. The critical factor will be the speed and scale at which the new formulation gains traction in the first quarter of 2026, thereby delivering a measurable contribution to the recovery of both revenue and earnings.